MAXONA announces first patient dosed in Phase 2 trial of MAX-001 for acute pain
MAXONA Pharmaceuticals reported that the first participant was dosed in its Phase 2 clinical trial of MAX-001 for acute pain following surgical extraction of impacted third molars (NCT07937657). The study plans to enroll 276 patients and evaluate safety and efficacy across a dose range.
Primary source
Company press release (PR Newswire), November 18, 2026
MAXONA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN MAX-001 CLINICAL TRIAL FOR ACUTE PAIN
Read the source: MAXONA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN MAX-001 CLINICAL TRIAL FOR ACUTE PAIN prnewswire.com
Machine-summarized from the source above; not independently reported. How we use automation